Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by westcoast1000on Nov 14, 2022 4:02pm
243 Views
Post# 35097745

repost from Yahoo board

repost from Yahoo board

The KOL talk did not offer much in terms of emotional impact. But these folks are science/medical types, not BD corporate types. They said what the data and the paper says. That's all they would feel justified in saying.

 

ONCY has said it is proceeding with discussions about the registration trial. That is all that can be said in that vein.

 

Overall, it is more of the same, in that the investment world basically is ignoring ONCY, despite the remarkable, surprising, encouraging results (insert your own adjective). I still do not understand why that is. No sensible person would believe there is "something wrong" with the results. The results are what they said. No more or less. Nor is their some hidden flaw that makes pela worth little (insert your own conspiracy theory here).

 

We now look to the future.

 

The bracelet trial results expected in the first half of the year will be a rerun of the former AWARE trial, with bigger samples.

 

This December we also get the WOO results that are again with Roche and tecentriq, this time with HR neg BC.

 

We await these trial results, as we have waited for others for some time. But these results will be much riper and further advanced trial results with a lot of supporting studies to back them up.

 

I think it will take a total buyout or a major partnership/equity participation that effectively sets a share price that cannot be ignored by the rest of the world before we see what we are waiting for.

<< Previous
Bullboard Posts
Next >>